US Patent

US7687075 — Colonic purgative composition with soluble binding agent

Composition of Matter · Assigned to Salix Pharmaceuticals Ltd · Expires 2028-06-22 · 2y remaining

Vulnerability score 22/100 Ironclad — strong claim type, well-established, deep family

What this patent protects

This patent protects novel colonic purgative compositions in a solid dosage form that improve patient tolerance and bowel cleansing quality.

USPTO Abstract

This invention relates to novel colonic purgative compositions in a solid dosage form, comprising at least one purgative and at least one soluble, or soluble, nonfermentable binder, such as polyethylene glycol. Further, this invention relates to methods of using the colonic purgative compositions. The present compositions and methods are designed to improve patient tolerance and compliance, while at the same time improving the quality of bowel cleansing. The formulations and methods of this invention are particularly useful to cleanse the bowel prior to diagnostic and surgical procedures and can also be employed in lower dosages as a laxative to promote elimination and/or to relieve constipation.

Drugs covered by this patent

Patent Metadata

Patent number
US7687075
Jurisdiction
US
Classification
Composition of Matter
Expires
2028-06-22
Drug substance claim
Yes
Drug product claim
Yes
Assignee
Salix Pharmaceuticals Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.